ライフサイエンスコーパス: toll

1 enza, influenza epidemics continue to take a toll.

2 can lead to higher economic losses and death tolls.

3 Antivirals can reduce death tolls.

4 f the epidemic in lockstep with rising death tolls.

5 Conditional over-expression of Toll-2 and wek at the adult critical period increased br

6 Toll-2 gain of function and neuronal activity at the cri

7 Toll-2 induced cycling of adult progenitor cells via a n

8 Focusing on Toll-2, loss of function caused apoptosis, neurite atrop

9 ifically, we show that, while the pattern of Toll activation in the early Drosophila embryo is robust

10 talyzed melanin formation, Spatzle-triggered Toll activation, and induced synthesis of antimicrobial

11 es and results in differential expression of Toll and Imd pathway effector genes, specifically in the

12 1 is induced by infections downstream of the Toll and Imd pathways and is necessary for iron relocati

13 r factor kappaB (NF-kappaB) immune pathways, Toll and Imd, revealing that these pathways also mediate

14 imicrobial peptides associated with both the Toll and Immune deficiency pathways.

15 spelaeus specimens recovered in Level 4 from Toll Cave (Moia, Catalonia, NE Iberian Peninsula).

16 The cave bears from Toll Cave show a microwear pattern like that of extant b

17 ds of vehicles along highways generated from toll collection systems, we attempt to establish the rel

18 Tolls demarcate a map of brain anatomical domains.

19 In seeking to stem the rising toll from OUD, expanding access to approved treatment su

20 ve to the binding of the TLR sorting adaptor Toll-IL1 receptor (TIR) domain-containing adaptor protei

21 Moreover, activation of the Toll immune signaling pathway in the susceptible strain

22 ting an evolutionarily conserved function of Toll in defense against DNA viruses.

23 Polymorphisms within and around Toll interacting protein (TOLLIP) are associated with th

24 Toll-interleukin 1 receptor domain NLRs (TNLs) converge

25 mice with mice lacking signaling through the Toll-Interleukin 1 Receptor Domain-Containing Adaptor Pr

26 evered axons degenerated via alpha/Armadillo/Toll-interleukin receptor homology domain (dSarm)/Axunde

27 of immune receptors containing an N-terminal Toll-interleukin-1 receptor-like domain (TNLs) in Arabid

28 ell known that TLR3 uses the adaptor protein Toll/interleukin-1 receptor (IL-1R) domain-containing ad

29 c complementation, and found that C15 in the Toll/interleukin-1 receptor (TIR) domain and L816 in the

30 this neurodegenerative process(5-8), and its Toll/interleukin-1 receptor (TIR) domain exerts its pro-

31 Sterile alpha and Toll/interleukin-1 receptor motif-containing protein 1 (

32 iffer in their N-terminal domains: these are Toll/interleukin-1 receptor resistance (TIR) domain-cont

33 iation primary response 88 adaptors, but not toll/interleukin-1 receptor/resistance [TIR] domain-cont

34 lper NLRs that is recruited by intracellular Toll-interleukin1-receptor (TIR) domain NLR receptors to

35 Innate responses to Toll like receptor (TLR) ligation decreased with treatme

36 eractions with the B cell receptor (BCR) and Toll like receptor (TLR) pathways.

37 Although the well-known Toll like receptor 9 (TLR9) agonist CpGODN has shown pro

38 Toll like receptors (TLRs) are critical receptors to res

39 Plasmacytoid dendritic cells (pDCs) express Toll like receptors (TLRs) that modulate the immune resp

40 ules showing inflammatory pathways linked to Toll-like and TNF receptor activation and arachidonic ac

41 n NLR native to Nicotiana benthamiana with a Toll-like interleukin-1 receptor (TIR) domain bound to t

42 Toll-like receptor (TLR) 2 recognizes and responds to th

43 Upon ex vivo stimulation with Toll-like receptor (TLR) 4 or TLR-2 agonists, monocytes

44 Much of this influence arises from Toll-like receptor (TLR) 4 or TLR2 signalling and, in th

45 urine X chromosome-encoded receptor proteins Toll-like receptor (TLR) 7 and TLR8 reportedly results i

46 onal deletion strategies in a mouse model of Toll-like receptor (TLR) 7-induced inflammation, that th

47 When administered with a potent Toll-like receptor (TLR) 7/8 agonist adjuvant, these nan

48 e we describe an aggressive in vivo model of Toll-like receptor (TLR) 9 dysregulation, based on bypas

49 FN-I amounts produced by pDCs in response to Toll-like receptor (TLR) activation.

50 the aggregation of multiple bacteria and the Toll-like receptor (TLR) agonists they produce.

51 In this study, we show that a toll-like receptor (TLR) and C-type lectin receptor (CLR

52 recognition receptors (PRRs), including the Toll-like receptor (TLR) family are promising targets fo

53 Synthetic Toll-like receptor (TLR) ligands are ideal adjuvants for

54 Pre-DC activation by toll-like receptor (TLR) ligands induces an antiviral st

55 terologous stimulants (killed pathogens) and Toll-like receptor (TLR) ligands.

56 Toll-like receptor (TLR) recruitment to phagosomes in de

57 of B cell receptor signaling in B cells and Toll-like receptor (TLR) signaling in macrophages.

58 me (MDS) and cell-intrinsic dysregulation of Toll-like receptor (TLR) signaling in MDS hematopoietic

59 gnificantly elevated post injury, indicating toll-like receptor (TLR) signaling may be involved in mu

60 tion of alternative mRNA splice forms in the Toll-like receptor (TLR) signaling pathway.

61 Toll-like receptor (TLR) stimulation shifts intracellula

62 Since Toll-like receptor (TLR)-4 can amplify PAF signaling, we

63 cytoid dendritic cells, where it potentiates toll-like receptor (TLR)-9 activation and IFN-alpha prod

64 oduction in recruited monocytes by enhancing Toll-like receptor (TLR)-induced glycolysis.

65 Herein, we report that levels of the Toll-like receptor (TLR)-related lnc interleukin (IL) 7

66 ell (LC) migration, but also MyD88-dependent Toll-like receptor (TLR)-stimulated DC activation.

67 of select cytokines upon stimulation of the Toll-like receptor (TLR)1-TLR2 heterodimer (referred to

68 Blocking antibodies against Toll-like receptor (TLR)1/TLR2, as well as small interfe

69 ntranasal costimulation with the lipopeptide Toll-like receptor (TLR)2/6 agonist, Pam2Cys (P2C), and

70 LPS stimulation indicates suppression of the Toll-like receptor (TLR)4 pathway.

71 of melanoma with intratumoral injections of Toll-like receptor 1/2 (TLR1/2) ligand Pam3CSK4 plus i.p

72 ent on the T. gondii mouse profilin receptor Toll-like receptor 11 (TLR11), but the ectopic expressio

73 of differential expression of genes such as Toll-like receptor 15, Toll-like receptor 21, and matrix

74 ly to host cell CD36 and to the complex CD36-Toll-like receptor 2 (TLR-2), but not to TLR-2 alone or

75 Toll-like receptor 2 (TLR2) agonists are lipopeptides po

76 e previously shown to engage human and mouse Toll-like receptor 2 (TLR2) and to inhibit mouse osteobl

77 ferentiation 14 (CD14) and the transmembrane toll-like receptor 2 (TLR2) are important receptors in t

78 Toll-like receptor 2 (TLR2) is an innate immune receptor

79 ssion profile was similar to that induced by toll-like receptor 2 (TLR2) ligand Pam3Cys, but differen

80 Toll-like receptor 2 (TLR2) plays a key role in innate i

81 We have previously demonstrated that toll-like receptor 2 (TLR2) signaling is critical for ne

82 this study, we examined the contribution of Toll-like receptor 2 (TLR2) to host resistance against M

83 stress response was found to be dependent on Toll-like receptor 2 (TLR2), as evident by reduced expre

84 This study investigated responses to Toll-like receptor 2 (TLR2)-driven extracellular signal-

85 ted proteins on the AML-EV surface activated Toll-like receptor 2 as the initiating event of Akt/mTOR

86 is bacterium evade immune recognition by the Toll-like receptor 2 family complex.

87 roteasome proteolysis, by treatment of TLR2 (Toll-like receptor 2)-engaged and TLR7 (Toll-like recept

88 We demonstrate that Toll-like receptor 2-deficient (TLR2(-/-)) mice are resi

89 universal T helper epitope, and a synthetic toll-like receptor 2-targeting moiety as a possible self

90 sion of genes such as Toll-like receptor 15, Toll-like receptor 21, and matrix metallopeptidase 1.

91 infection of EECs significantly reduced both Toll-like receptor 3 (TLR3) and TLR4 mRNA expression at

92 s nonsynonymous variant (c.2324C > T) in the Toll-like receptor 3 (TLR3) gene resulting in formation

93 )-stimulator of interferon genes (STING) and Toll-like receptor 3 (TLR3) pathways.

94 -1B, which mediates the polarized sorting of Toll-like receptor 3 (TLR3) towards the basolateral side

95 n (LOF) at the 13 human loci known to govern Toll-like receptor 3 (TLR3)- and interferon regulatory f

96 ophage pro-inflammatory responses, represses Toll-like receptor 3 and virus-induced expression of IFN

97 Toll-like receptor 3 responses that were unaffected in A

98 reactivation capacity further increased upon Toll-like receptor 3 stimulation with poly(I.C) double-s

99 This study shows that rs3775291 SNP at Toll-like receptor 3, which triggers type I interferon a

100 nd mRNA translation lead to hypothesize that toll-like receptor 4 (TLR4) activation reduced LNP-media

101 DM), which is similar to that induced by the Toll-like receptor 4 (TLR4) agonist lipopolysaccharide.

102 ined to be associated with downregulation of Toll-like receptor 4 (TLR4) expression on the surface of

103 L1 as a critical structural component of the Toll-like receptor 4 (TLR4) immune signal transduction p

104 s, we first evaluated the role of nociceptor Toll-like receptor 4 (TLR4) in OIH and priming induced b

105 critical role of innate immune signaling via Toll-like receptor 4 (TLR4) in the pathogenesis of dyspl

106 Sensing of pathogens by Toll-like receptor 4 (TLR4) induces an inflammatory resp

107 tirely clear, current evidence suggests that Toll-like receptor 4 (TLR4) is a key player in the mecha

108 r advanced glycation end products (RAGE) and Toll-like receptor 4 (TLR4) is implicated in COPD.

109 We investigated the role of an endogenous Toll-like receptor 4 (TLR4) ligand, fibronectin-EDA (FN-

110 xamined the effect of innate immune receptor Toll-like receptor 4 (TLR4) on excitability of the hippo

111 ed by a paracrine mechanism that engaged the Toll-like receptor 4 (TLR4) on hair cells to protect the

112 mponents such as lipopolysaccharide (LPS) by Toll-like receptor 4 (TLR4) on macrophages induces a rob

113 genes (STING) pathway and an agonist of the Toll-like receptor 4 (TLR4) pathway.

114 driven by microbial-dependent activation of toll-like receptor 4 (TLR4) signaling and subsequent eng

115 -TOF MS), gas chromatography (GC), SDS-PAGE, Toll-like receptor 4 (TLR4) stimulation, and immunoblot

116 In male rats, HMWH also signals via Toll-like receptor 4 (TLR4), and AS-ODN for TLR4 mRNA ad

117 s can be induced by endotoxin stimulation of Toll-like receptor 4 (TLR4), resulting in an ameliorated

118 conditions were previously found to activate Toll-like receptor 4 (TLR4), resulting in expression of

119 einphagy requires the presence of microglial Toll-like receptor 4 (TLR4), which induces transcription

120 production by modulating host immunity in a Toll-like receptor 4 (TLR4)-dependent manner, a signalin

121 rickettsiae activate ASC inflammasome via a Toll-like receptor 4 (TLR4)-dependent mechanism.

122 ors to evaluate the role of various genes in Toll-like receptor 4 (TLR4)-induced necroptosis.

123 ells, and TNFalpha secretion is dependent on toll-like receptor 4 (TLR4).

124 evelopment accelerates after deletion of the Toll-like receptor 4 (TLR4).

125 e the intestine's innate immune response via toll-like receptor 4 (TLR4).

126 effects which are mediated partially through Toll-like receptor 4 (TLR4).

127 these cytokines during bacterial sepsis via Toll-like receptor 4 (TLR4)/MyD88 sensing of lipopolysac

128 Mechanistically, Toll-like receptor 4 (TLR4, LPS receptor)-sphingosine ki

129 cyte-specific deletion of YAP (YAP( KO) ) or Toll-like receptor 4 (TLR4; TLR4( KO) ), and animals wer

130 These alarmins bind to the Toll-like receptor 4 and prime the nod-like receptor fam

131 show that upon cancer-induced activation of Toll-like receptor 4 in skeletal muscle, p38beta MAPK ph

132 Although we report that Toll-like receptor 4 is expressed in both excitatory and

133 Toll-like receptor 4 positive (TLR4(+) ) macrophages wer

134 entrain qualitatively different responses to toll-like receptor 4 signaling in vivo.

135 ses both in vivo and in vitro LPS stimulates Toll-like receptor 4, an important mediator of the brain

136 in their livers and spleens for months, but Toll-like receptor 4-deficient animals succumbed to thes

137 RI had increased disulfide-HMGB1 and induced Toll-like receptor 4-dependent tumor necrosis factor alp

138 d antagonizing the activation of LPS-induced Toll-like receptor 4-myeloid differentiation factor 2 (T

139 mechanisms by which inflammation - driven by Toll-like receptor 4-regulated cytokines, immune cells a

140 stic cells by anticardiolipin occurs through Toll-like receptor 4.

141 f IL-1R8, diminishing activation mediated by toll-like receptor 4.

142 to Kupffer cells (KCs) and co-localized with toll-like receptor 4.

143 entially detected by host receptors like the Toll-like receptor 4/myeloid differentiation factor 2 co

144 LPS is recognized by the Toll-like receptor 4/myeloid differentiation factor-2 (T

145 ating that miR-147 upregulation inhibits the Toll-like receptor 4/NF-kappaB pathway.

146 ponsible for this pro-viral activity was the Toll-Like Receptor 5 (TLR5) agonist flagellin.

147 acid epitope in flagellin recognized by the Toll-like receptor 5 (TLR5).

148 response induced by flagellin activation of Toll-like Receptor 5 cell signalling is augmented follow

149 We treated mice topically with the Toll-like receptor 7 (TLR7) agonist imiquimod (IMQ) to a

150 e production, with IRF5 acting downstream of Toll-like receptor 7 (TLR7) and, possibly, retinoic acid

151 Toll-like receptor 7 (TLR7) is an established therapeuti

152 Our previous study demonstrated that Toll-like receptor 7 (TLR7) is essential in the inductio

153 Using Toll-like receptor 7 (TLR7)-dependent mouse models of sy

154 that internalize red blood cells develop in Toll-like receptor 7 (TLR7)-driven inflammation.

155 co-delivery of a hydrophobic small-molecule toll-like receptor 7 agonist, imiquimod (IMD), and a hyd

156 Resiquimod (R848) is a toll-like receptor 7 and 8 (TLR7/8) agonist with potent

157 on and revealed that IRF5 acts downstream of Toll-like receptor 7 and possibly retinoic acid-inducibl

158 rticoids impair upstream B cell receptor and Toll-like receptor 7 signaling, reduce transcriptional o

159 LR2 (Toll-like receptor 2)-engaged and TLR7 (Toll-like receptor 7)/TLR8 (Toll-like receptor 8)-engage

160 vaccine that links neoantigen peptides to a Toll-like receptor 7/8 agonist (SNP-7/8a), we show how t

161 We administered the Toll-like receptor 7/8 agonist resiquimod (R848; a synth

162 The Toll-like receptor 8 (TLR8) has an important role in inn

163 Toll-like receptor 8 (TLR8) recognizes pathogen-derived

164 an oral selective small molecule agonist of toll-like receptor 8 in clinical development for the tre

165 ngaged and TLR7 (Toll-like receptor 7)/TLR8 (Toll-like receptor 8)-engaged CD14(+) monocytes with ONX

166 lites and peptidoglycan into host cells, and Toll-like receptor 9 (TLR9) activation is attributed to

167 pathology, CpG 1018, a Th1-biasing synthetic toll-like receptor 9 (TLR9) agonist was selected as an a

168 Toll-like receptor 9 (TLR9) agonists have gained tractio

169 Toll-like receptor 9 (TLR9) is a regulator of disease pa

170 role for the innate immune-sensing molecule Toll-like receptor 9 (TLR9)(4), and its interaction with

171 osis-induced apoptosis in human PMNs through Toll-like receptor 9 (TLR9)-mediated release of neutroph

172 NA and contributed to pattern recognition by Toll-like receptor 9 (TLR9).

173 ucleotide conjugated to a scavenger receptor/Toll-like receptor 9 agonist (C-miR146a).

174 imulation with a CpG oligodeoxynucleotide, a Toll-like receptor 9 agonist, evokes changes in the cent

175 vation in human monocytes is mediated by the Toll-like receptor adapter protein SCIMP.

176 quires signaling from the cytokine IL-34 and Toll-like receptor adaptor MyD88, and occurs in coordina

177 Activation of PMs by Toll-like receptor agonists and live bacteria altered le

178 o type I IFNs promoted enhanced responses to Toll-like receptor agonists.

179 ein, we describe an adjuvant consisting of a Toll-like receptor and C-type lectin receptor agonist pa

180 on from human monocytes requires cooperative Toll-like receptor and IFNalpha/beta signaling.

181 show that RNAi depletion of IL-17RD enhances Toll-like receptor and IL-17A signaling in colon adenoca

182 -cDC2s matured in response to cell-intrinsic Toll-like receptor and type 1 interferon receptor signal

183 oxychloroquine (HCQ), an orally administered Toll-like receptor antagonist widely used in lupus inclu

184 It potently amplifies inflammation via Toll-like receptor four and is antimicrobial as part of

185 s reveal a heretofore undescribed role for a Toll-like receptor in skeletal-muscle AMPK activation an

186 Liposomal codelivery of tumor antigen and Toll-like receptor ligand to CD169(+) moDCs and Axl(+) C

187 Toll-like receptor ligands in indoor dust act as environ

188 n immune response in cells activated by RNA, Toll-like receptor ligands, cGAMP, or recombinant interf

189 onse may be further enhanced by inclusion of Toll-like receptor ligands, which many VLPs naturally pa

190 ZC3H12A, and genes in the interleukin 17 and Toll-like receptor pathways, under positive selection in

191 eptor for advanced glycation endproducts and Toll-like receptor proteins 2 and 4.

192 asmic reticulum stress, HIF-1 signaling, and Toll-like receptor signaling as enriched after palmitic

193 ical evidence support the role of macrophage Toll-like receptor signaling in maternal anti-SSA/Ro-med

194 ve growth factor signaling and innate immune toll-like receptor signaling in MDD.

195 naling, C-type lectin receptor signaling and Toll-like receptor signaling pathways.

196 ed macrophages at least in part by enhancing Toll-like receptor signaling via the up-regulation of WD

197 erb-b2 receptor tyrosine kinase (Erbb), and Toll-like receptor signaling were enriched in lysates of

198 GE(2) Mechanistically, WDFY1 was involved in Toll-like receptor signaling, and its down-regulation in

199 al substrates of the HOIL-1 E3 ligase during Toll-like receptor signaling.

200 ncomitant cooperation of B-cell receptor and Toll-like receptor signaling; inhibition of both pathway

201 reby pro-inflammatory cytokine responses and Toll-like receptor signalling are inhibited following PL

202 A Toll-like receptor signalling molecule, TRAM, was assess

203 ly engaged at ATF3-bound sites that suppress Toll-like receptor signalling.

204 Toll-like receptor stimulated macrophages from KI mice s

205 w that CH25H is induced by ZIKV infection or Toll-like receptor stimulation.

206 ated with two mRNA modules enriched for TLR (Toll-like receptor) and T-helper cell type 17 (Th17) sig

207 n of other innate immune pathways, including toll-like receptor, interleukin and chemokine signaling.

208 vators of the pattern recognition receptors, toll-like receptor-2 (TLR2) and -4 (TLR4).

209 attenuated pro-inflammatory responses toward Toll-like receptor-2 and -4 stimulation.

210 also exhibits anti-inflammatory effects in a Toll-like Receptor-4 (TLR-4) dependent manner.

211 The lipopolysaccharide (LPS)- toll-like receptor-4 (TLR4) pathway plays an important r

212 ene Expression Array Plates system for genes Toll-like receptor-4 (TLR4), high-mobility group box 1,

213 lls presented increased CD11b activation and toll-like receptor-4 expression.

214 the activated phenotype, IFN-alpha inhibited Toll-like receptor-induced cytokine production and monoc

215 ds significantly inhibited the expression of Toll-like receptor-induced inflammatory genes in vitro a

216 -kB ubiquitination and degradation, prevents Toll-like receptor-induced pro-inflammatory cytokine exp

217 phages, expression of LACC1 was required for toll-like receptor-induced uptake of bacteria, which req

218 These glycosphingolipids are found in Toll-like receptor-stimulated dendritic cells (DC) as se

219 ne-stimulatory drugs such as agonists of the Toll-like receptors (TLR) 7/8 are potent activators of a

220 Toll-like receptors (TLR) are a group of receptors that

221 ted single nucleotide polymorphisms (SNP) of toll-like receptors (TLR), NOD-like receptors (NLR) and

222 Activation of toll-like receptors (TLR1, TLR5, TLR6) and downstream ma

223 The Toll-like receptors (TLRs) 7 and 8 play an important rol

224 biological significance of crosstalk between Toll-like receptors (TLRs) and B cell receptors (BCRs) i

225 udy, we demonstrated that gene expression of Toll-like receptors (TLRs) and myeloid differentiation p

226 Toll-like receptors (TLRs) are a class of proteins that

227 Moreover, we show that Toll-like receptors (TLRs) are critical for shaping the

228 Proinflammatory responses induced by Toll-like receptors (TLRs) are dependent on the activati

229 RNA-sensing Toll-like receptors (TLRs) are often described as antivi

230 Toll-like receptors (TLRs) are the pattern recognition r

231 Toll-like receptors (TLRs) coupled to intracellular sign

232 Toll-like receptors (TLRs) have a crucial role in the re

233 a or their products affect the adult ENS via toll-like receptors (TLRs) in mice.

234 displayed on the pathogen are recognized by Toll-like receptors (TLRs) on the host cell, it activate

235 Toll-like receptors (TLRs) play a central role in both t

236 Toll-like receptors (TLRs) play a crucial role in the in

237 We sought to investigate the roles that Toll-like receptors (TLRs) play in A. baumannii OMV-medi

238 Innate immune receptors such as toll-like receptors (TLRs) provide critical molecular li

239 Surface-exposed Toll-like receptors (TLRs) such as TLR2 and TLR4 survey

240 ernal administration of agents that activate toll-like receptors (TLRs), a class of pattern recogniti

241 to our understanding of these events are the Toll-like receptors (TLRs), an evolutionarily ancient fa

242 veal a major contribution of pDCs, endosomal Toll-like receptors (TLRs), and IFN-I to this pathway.

243 pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs), and produce inflammatory med

244 pathways, including those through endosomal Toll-like receptors (TLRs), Fc gamma receptors (FcgammaR

245 other innate immune receptors, for example, Toll-like receptors (TLRs), that recognize ligands deriv

246 r, BCAP suppresses inflammatory signaling by Toll-like receptors (TLRs).

247 al drivers of such neuroinflammation include toll-like receptors (TLRs).

248 atidylglycerol can inhibit the activation of toll-like receptors 2 and 4 of the innate immune system

249 flammasome via caspase-8 and dimerization of Toll-like receptors 2 and 4.

250 tides (ASOs) can have opposing activities on Toll-Like Receptors 7 and 8 (TLR7/8), leading to diverge

251 Thus, the concerted activation of both Toll-like receptors and C-type lectin receptors is requi

252 aled stable interactions of the vaccine with Toll-Like Receptors and MHC Receptors.

253 distinct features of bona fide RNA sensors, Toll-like receptors and retinoic-acid inducible gene-I (

254 Toll-like receptors are critical in the early detection

255 acological blockade of mu opioid receptor or Toll-like receptors complex failed to alter, while block

256 SATB1 was positively correlated with toll-like receptors expression, suggesting innate immune

257 ry of pattern-recognition receptors, such as Toll-like receptors or IL-1 family receptors.

258 ated by germ line-encoded receptors, such as Toll-like receptors or natural killer receptors, are com

259 In the present study we show that the toll-like receptors TLR2 and TLR4 inhibited the diet-ind

260 TREM2, PLCgamma2 also signals downstream of Toll-like receptors to mediate inflammatory responses.

261 ith inflammatory responses driven by TNF and Toll-like receptors via NF-kappaB, eicosanoid biosynthes

262 between 12 and 18 h after the activation of Toll-like receptors with proinflammatory stimuli and tha

263 n genes (STING) pathway, rather than through Toll-like receptors, and result in limited systemic cyto

264 side downstream of immune sensors, including Toll-like receptors, nucleotide-binding oligomerization

265 recipient cells via activation of endosomal Toll-like receptors.

266 ity towards increased T-cell reactivity upon Toll-like-receptor stimulation.

267 5) increased hypothalamic microglia density, toll-like-receptor-4 (Tlr4), and the inhibitor-NF-kappa-

268 Imiquimod is a topical toll-like-receptor-7 agonist currently used for treating

269 hage colony-stimulating factor (GM-CSF), the Toll-like-receptor-9 agonist cytosine-guanosine oligodeo

270 e not effector cells, have lost capacity for Toll-like-receptor-mediated cytokine production and do n

271 nhibitor of Toll signalling, suggesting that Toll mediates antiviral defense against Kallithea virus

272 eir negative regulators, including those for Toll, melanization, and phagocytosis pathways.

273 ansplantation and limit the growing indirect toll of an already deadly disease.

274 oth the pragmatics of care and the emotional toll of caregiving.

275 site systems to help reveal the hidden death toll of pathogens on wildlife hosts.

276 The human and social toll of the coronavirus disease 2019 (COVID-19) pandemic

277 given the emotional, physical, and financial toll of these claims on patients, providers, and the hea

278 and risk factors is essential to reduce the toll of these infections.

279 mics, suggesting a significant mental health toll on clinicians.

280 heir different combinations, inflict a heavy toll on crop productivity worldwide.

281 structural drivers of unjust isms and their toll on environmental degradation, climate change, and h

282 -19) pandemic is exacting a disproportionate toll on ethnic minority communities and magnifying exist

283 he COVID-19 pandemic has taken a significant toll on people worldwide, and there are currently no spe

284 COVID-19 is also anticipated to take a toll on the nervous system in the long term.

285 This was associated with constitutive Toll pathway activation triggered by excess peptidoglyca

286 We found that KV suppresses the Toll pathway and identified gp83 as a KV-encoded protein

287 a was shown to enhance the expression of the Toll pathway-mediated antimicrobial peptides when the fl

288 y cells establish polarity in the absence of Toll receptor activity, indicating the presence of addit

289 esults demonstrate that the Tartan/Ten-m and Toll receptor systems together create a high-resolution

290 as more effective than HCQ at inhibiting the toll receptor-mediated production of TNF-alpha and IL-6

291 Here, we asked if Toll receptors are involved.

292 rleukin-1 analog Spatzle, which then acts on Toll receptors on R5 neurons.

293 Through their topographic distribution, Toll receptors regulate neuronal number and brain size,

294 nudivirus (DiNV) suppresses D. melanogaster Toll signalling, suggesting an evolutionarily conserved

295 ncoded protein gp83 as a potent inhibitor of Toll signalling, suggesting that Toll mediates antiviral

296 wn of escargot, or overactivation of mTor or Toll signalling.

297 neighboring cells via a mechanism involving Toll, Spz factors, and the Spz inhibitor Necrotic.

298 Constant knock-down of multiple Tolls synergistically reduced brain size.

299 Furthermore, active Toll, the receptor that dissociates Cactus from Dorsal,

300 r a million deaths worldwide, and this death toll will be much higher before effective treatments and